RCMI Coordinating Center (RCMI CC) Header Logo

Connection

David Calhoun to Humans

This is a "connection" page, showing publications David Calhoun has written about Humans.
Connection Strength

3.793
  1. Matanes F, Siddiqui M, Velasco A, Sharifov O, Kreps E, Dudenbostel T, Judd EK, Zhang B, Lloyd SG, Oparil S, Calhoun DA. Adverse cardiac remodeling is absent in patients with true controlled resistant hypertension. J Clin Hypertens (Greenwich). 2023 05; 25(5):416-425.
    View in: PubMed
    Score: 0.044
  2. Dudenbostel T, Li P, Calhoun DA. Paradoxical Increase of 24-Hour Urinary Aldosterone Levels in Obese Patients With Resistant Hypertension on a High Salt Diet. Am J Hypertens. 2021 06 22; 34(6):600-608.
    View in: PubMed
    Score: 0.039
  3. Thomas SJ, Siddiqui M, Judd E, Moore D, Harding SM, Oparil S, Calhoun D. Obstructive sleep apnea is more severe in men but not women with refractory hypertension compared with controlled resistant hypertension. J Hypertens. 2021 02 01; 39(2):286-291.
    View in: PubMed
    Score: 0.038
  4. Siddiqui M, Judd EK, Zhang B, Dudenbostel T, Carey RM, Oparil S, Calhoun DA. Masked Uncontrolled Hypertension Is Accompanied by Increased Out-of-Clinic Aldosterone Secretion. Hypertension. 2021 02; 77(2):435-444.
    View in: PubMed
    Score: 0.038
  5. Siddiqui M, Bhatt H, Judd EK, Oparil S, Calhoun DA. Reserpine Substantially Lowers Blood Pressure in Patients With Refractory Hypertension: A Proof-of-Concept Study. Am J Hypertens. 2020 08 04; 33(8):741-747.
    View in: PubMed
    Score: 0.037
  6. Stokes ES, Gilchrist ML, Calhoun DH. Prediction of improved therapeutics for fabry disease patients generated by mutagenesis of the a-galactosidase A active site, dimer interface, and glycosylation region. Protein Expr Purif. 2020 11; 175:105710.
    View in: PubMed
    Score: 0.037
  7. Kwon Y, Stafford PL, Lim DC, Park S, Kim SH, Berry RB, Calhoun DA. Blood pressure monitoring in sleep: time to wake up. Blood Press Monit. 2020 Apr; 25(2):61-68.
    View in: PubMed
    Score: 0.036
  8. Cai A, Siddiqui M, Judd EK, Oparil S, Calhoun DA. Aortic blood pressure and arterial stiffness in patients with controlled resistant and non-resistant hypertension. J Clin Hypertens (Greenwich). 2020 02; 22(2):167-173.
    View in: PubMed
    Score: 0.036
  9. Siddiqui M, Judd EK, Dudenbostel T, Gupta P, Tomaszewski M, Patel P, Oparil S, Calhoun DA. Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension. Hypertension. 2020 02; 75(2):510-515.
    View in: PubMed
    Score: 0.035
  10. Siddiqui M, Judd EK, Dudenbostel T, Zhang B, Gupta P, Tomaszewski M, Patel P, Oparil S, Calhoun DA. Masked Uncontrolled Hypertension Is Not Attributable to Medication Nonadherence. Hypertension. 2019 09; 74(3):652-659.
    View in: PubMed
    Score: 0.034
  11. Flack JM, Calhoun D. The ACC/AHA and ESC/ESH Hypertension Guidelines: Contrasting Versions of Idiosyncratic Excellence. Am J Hypertens. 2019 07 17; 32(8):705-708.
    View in: PubMed
    Score: 0.034
  12. Calhoun DA. The Year in Clinical Hypertension From Other Pages. Am J Hypertens. 2019 04 22; 32(5):441-444.
    View in: PubMed
    Score: 0.034
  13. Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of Resistant and Refractory Hypertension. Circ Res. 2019 03 29; 124(7):1061-1070.
    View in: PubMed
    Score: 0.034
  14. Siddiqui M, Calhoun DA. Blood Pressure Measurement Challenges in Severely Obese Patients. Am J Hypertens. 2019 01 15; 32(2):139-140.
    View in: PubMed
    Score: 0.033
  15. Calhoun DA, Schiffrin EL, Flack JM. Resistant Hypertension: An Update. Am J Hypertens. 2019 01 01; 32(1):1-3.
    View in: PubMed
    Score: 0.033
  16. Siddiqui M, Judd EK, Jaeger BC, Bhatt H, Dudenbostel T, Zhang B, Edwards LJ, Oparil S, Calhoun DA. Out-of-Clinic Sympathetic Activity Is Increased in Patients With Masked Uncontrolled Hypertension. Hypertension. 2019 01; 73(1):132-141.
    View in: PubMed
    Score: 0.033
  17. Velasco A, Siddiqui M, Kreps E, Kolakalapudi P, Dudenbostel T, Arora G, Judd EK, Prabhu SD, Lloyd SG, Oparil S, Calhoun DA. Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes. Hypertension. 2018 08; 72(2):343-349.
    View in: PubMed
    Score: 0.032
  18. Siddiqui M, Phillips RA, Bursztyn M, Sica D, Velasco A, Judd EK, Dudenbostel T, Lloyd SG, Oparil S, Calhoun DA. Case of Refractory Hypertension Controlled After Aortic and Mitral Valve Replacement and Coronary Artery Bypass Grafting. Hypertension. 2018 07; 72(1):3-9.
    View in: PubMed
    Score: 0.032
  19. Calhoun DA. Fluid retention, aldosterone excess, and treatment of resistant hypertension. Lancet Diabetes Endocrinol. 2018 06; 6(6):431-433.
    View in: PubMed
    Score: 0.031
  20. Valaiyapathi B, Calhoun DA. Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome. Curr Hypertens Rep. 2018 03 19; 20(3):23.
    View in: PubMed
    Score: 0.031
  21. Calhoun DA. Medical Versus Surgical Treatment of Primary Aldosteronism. Hypertension. 2018 04; 71(4):566-568.
    View in: PubMed
    Score: 0.031
  22. Cai A, Calhoun DA. Antihypertensive Medications and Falls in the Elderly. Am J Hypertens. 2018 02 09; 31(3):281-283.
    View in: PubMed
    Score: 0.031
  23. Calhoun DA, Grassi G. True versus pseudoresistant hypertension. J Hypertens. 2017 12; 35(12):2367-2368.
    View in: PubMed
    Score: 0.031
  24. Tolosa JN, Calhoun DA. Maternal and neonatal demographics of macrosomic infants admitted to the neonatal intensive care unit. J Perinatol. 2017 12; 37(12):1292-1296.
    View in: PubMed
    Score: 0.030
  25. Siddiqui M, Judd EK, Oparil S, Calhoun DA. White-Coat Effect Is Uncommon in Patients With Refractory Hypertension. Hypertension. 2017 09; 70(3):645-651.
    View in: PubMed
    Score: 0.030
  26. Calhoun DA. Sleep disorders and hypertension risk. J Hum Hypertens. 2017 06; 31(6):371-372.
    View in: PubMed
    Score: 0.030
  27. Cai A, Calhoun DA. Resistant Hypertension: An Update of Experimental and Clinical Findings. Hypertension. 2017 07; 70(1):5-9.
    View in: PubMed
    Score: 0.029
  28. Ghazi L, Dudenbostel T, Hachem ME, Siddiqui M, Lin CP, Oparil S, Calhoun DA. 11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension. Am J Hypertens. 2017 May 01; 30(5):518-523.
    View in: PubMed
    Score: 0.029
  29. Siddiqui M, Calhoun DA. Refractory versus resistant hypertension. Curr Opin Nephrol Hypertens. 2017 01; 26(1):14-19.
    View in: PubMed
    Score: 0.029
  30. Thomas SJ, Calhoun D. Sleep, insomnia, and hypertension: current findings and future directions. J Am Soc Hypertens. 2017 02; 11(2):122-129.
    View in: PubMed
    Score: 0.029
  31. Dudenbostel T, Calhoun DA. Effects of Spironolactone and Renal Denervation Treatment on Blood Pressure and Its Variability-Different Aspects of Hypertension Treatment. Am J Hypertens. 2017 01; 30(1):12-15.
    View in: PubMed
    Score: 0.028
  32. Biaggioni I, Calhoun DA. Sympathetic Activity, Hypertension, and The Importance of a Good Night's Sleep. Hypertension. 2016 12; 68(6):1338-1339.
    View in: PubMed
    Score: 0.028
  33. Dudenbostel T, Calhoun DA. Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension. Am J Hypertens. 2017 Feb; 30(2):103-109.
    View in: PubMed
    Score: 0.028
  34. Calhoun DA. Spironolactone versus renal nerve denervation for treatment of uncontrolled resistant hypertension. J Hypertens. 2016 09; 34(9):1701-3.
    View in: PubMed
    Score: 0.028
  35. Calhoun DA. Renal Nerve Denervation, Adherence, and Management of Resistant Hypertension. Circulation. 2016 09 20; 134(12):858-60.
    View in: PubMed
    Score: 0.028
  36. Dudenbostel T, Ghazi L, Liu M, Li P, Oparil S, Calhoun DA. Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. Hypertension. 2016 10; 68(4):995-1003.
    View in: PubMed
    Score: 0.028
  37. Ghazi L, Dudenbostel T, Lin CP, Oparil S, Calhoun DA. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. J Hypertens. 2016 May; 34(5):1005-10.
    View in: PubMed
    Score: 0.027
  38. Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure. Hypertension. 2016 06; 67(6):1085-92.
    View in: PubMed
    Score: 0.027
  39. Pimenta E, Calhoun DA. Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension? Curr Hypertens Rep. 2016 Apr; 18(4):25.
    View in: PubMed
    Score: 0.027
  40. Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens. 2016 06; 10(6):493-9.
    View in: PubMed
    Score: 0.027
  41. Judd E, Calhoun DA. Obesity, African American Race, Chronic Kidney Disease, and Resistant Hypertension: The Step Beyond Observed Risk. Hypertension. 2016 Feb; 67(2):275-7.
    View in: PubMed
    Score: 0.027
  42. Siddiqui M, Dudenbostel T, Calhoun DA. Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure. Can J Cardiol. 2016 05; 32(5):603-6.
    View in: PubMed
    Score: 0.026
  43. Calhoun DA. Editorial comment: change in leadership. J Hum Hypertens. 2015 Jun; 29(6):339.
    View in: PubMed
    Score: 0.026
  44. Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure. Hypertension. 2015 Jul; 66(1):126-33.
    View in: PubMed
    Score: 0.026
  45. Breaux-Shropshire TL, Whitt L, Oster RA, Lewis D, Shropshire TS, Calhoun DA. Results of an Academic, Health Care Worksite Weight Loss Contest for Southeastern Americans: Scale Back Alabama 2011-2013. Workplace Health Saf. 2015 Apr; 63(4):165-9.
    View in: PubMed
    Score: 0.025
  46. Gonzaga C, Bertolami A, Bertolami M, Amodeo C, Calhoun D. Obstructive sleep apnea, hypertension and cardiovascular diseases. J Hum Hypertens. 2015 Dec; 29(12):705-12.
    View in: PubMed
    Score: 0.025
  47. Judd E, Calhoun DA. Management of hypertension in CKD: beyond the guidelines. Adv Chronic Kidney Dis. 2015 Mar; 22(2):116-22.
    View in: PubMed
    Score: 0.025
  48. Meghdari M, Gao N, Abdullahi A, Stokes E, Calhoun DH. Carboxyl-terminal truncations alter the activity of the human a-galactosidase A. PLoS One. 2015; 10(2):e0118341.
    View in: PubMed
    Score: 0.025
  49. Breaux-Shropshire TL, Whitt L, Griffin RL, Shropshire AT, Calhoun DA. Characterizing workers participating in a worksite wellness health screening program using blood pressure control, self-monitoring, medication adherence, depression, and exercise. Workplace Health Saf. 2014 Jul; 62(7):292-300.
    View in: PubMed
    Score: 0.024
  50. Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, Safford MM, Muntner P. Response to should more significance be granted to medication response to antihypertensives in patients with resistant hypertension? Hypertension. 2014 Apr; 63(4):e84.
    View in: PubMed
    Score: 0.024
  51. Irvin MR, Booth JN, Shimbo D, Lackland DT, Oparil S, Howard G, Safford MM, Muntner P, Calhoun DA. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens. 2014 Jun; 8(6):405-13.
    View in: PubMed
    Score: 0.024
  52. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Response to Comment on optimal treatment for resistant hypertension: the missing data on pulse wave velocity. Hypertension. 2014 Mar; 63(3):e17-8.
    View in: PubMed
    Score: 0.024
  53. Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014 Aug; 28(8):463-8.
    View in: PubMed
    Score: 0.023
  54. Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, Safford MM, Muntner P. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014 Mar; 63(3):451-8.
    View in: PubMed
    Score: 0.023
  55. Calhoun DA. Apparent and true resistant hypertension: why not the same? J Am Soc Hypertens. 2013 Nov-Dec; 7(6):509-11.
    View in: PubMed
    Score: 0.023
  56. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013 Oct; 62(4):691-7.
    View in: PubMed
    Score: 0.023
  57. Flores FX, Ojeda FJ, Calhoun DA. Bartter syndrome: presentation in an extremely premature neonate. J Perinatol. 2013 Aug; 33(8):661-2.
    View in: PubMed
    Score: 0.023
  58. Pimenta E, Calhoun DA. Response. Chest. 2013 Aug; 144(2):720.
    View in: PubMed
    Score: 0.023
  59. Calhoun DA, Lacourci?re Y, Crikelair N, Jia Y, Glazer RD. Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. Curr Med Res Opin. 2013 Aug; 29(8):901-10.
    View in: PubMed
    Score: 0.023
  60. Pimenta E, Stowasser M, Gordon RD, Harding SM, Batlouni M, Zhang B, Oparil S, Calhoun DA. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest. 2013 Apr; 143(4):978-983.
    View in: PubMed
    Score: 0.022
  61. Moreno H, Calhoun DA. True resistant hypertension: definition and prevalence. J Hypertens. 2012 Nov; 30(11):2241-2; author reply 2242-2243.
    View in: PubMed
    Score: 0.022
  62. Calhoun DA. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med. 2013; 64:233-47.
    View in: PubMed
    Score: 0.021
  63. Pimenta E, Calhoun DA. Hypertensive crisis: forget the numbers. J Hypertens. 2012 May; 30(5):882-3.
    View in: PubMed
    Score: 0.021
  64. Clark D, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol. 2012 May; 28(3):318-25.
    View in: PubMed
    Score: 0.021
  65. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation. 2012 Apr 03; 125(13):1594-6.
    View in: PubMed
    Score: 0.021
  66. Judd E, Calhoun DA. Hypertension and orthostatic hypotension in older patients. J Hypertens. 2012 Jan; 30(1):38-9.
    View in: PubMed
    Score: 0.020
  67. Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, Cofield SS, Oparil S, Calhoun DA. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012 Jan; 14(1):7-12.
    View in: PubMed
    Score: 0.020
  68. Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, M?nard J. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011 Nov 01; 124(18):1945-55.
    View in: PubMed
    Score: 0.020
  69. Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich). 2011 Sep; 13(9):644-8.
    View in: PubMed
    Score: 0.020
  70. Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'Italia LJ, Cofield SS, Oparil S, Calhoun DA. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012 Aug; 26(8):502-6.
    View in: PubMed
    Score: 0.020
  71. Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens. 2012 May; 26(5):281-7.
    View in: PubMed
    Score: 0.020
  72. Ahmed MI, Calhoun DA. Resistant hypertension: bad and getting worse. Hypertension. 2011 Jun; 57(6):1045-6.
    View in: PubMed
    Score: 0.019
  73. Lacourci?re Y, Crikelair N, Glazer RD, Yen J, Calhoun DA. 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens. 2011 Oct; 25(10):615-22.
    View in: PubMed
    Score: 0.019
  74. Ahmed MI, Calhoun DA. Apparent resistant hypertension and medication adherence. Hypertens Res. 2011 Jan; 34(1):41-2.
    View in: PubMed
    Score: 0.019
  75. Acelajado MC, Calhoun DA. Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment. Cardiol Clin. 2010 Nov; 28(4):639-54.
    View in: PubMed
    Score: 0.019
  76. Pimenta E, Calhoun DA. Treatment of resistant hypertension. J Hypertens. 2010 Nov; 28(11):2194-5.
    View in: PubMed
    Score: 0.019
  77. Acelajado MC, Pimenta E, Calhoun DA. Salt and aldosterone: a concert of bad effects. Hypertension. 2010 Nov; 56(5):804-5.
    View in: PubMed
    Score: 0.019
  78. Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, Oparil S, Cofield SS, Calhoun DA. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med. 2010 Aug 15; 6(4):363-8.
    View in: PubMed
    Score: 0.018
  79. Calhoun DA, Sharma K. The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin. 2010 Aug; 28(3):517-27.
    View in: PubMed
    Score: 0.018
  80. Calhoun DA, Harding SM. Sleep and hypertension. Chest. 2010 Aug; 138(2):434-43.
    View in: PubMed
    Score: 0.018
  81. Calhoun DA. Obstructive sleep apnea and hypertension. Curr Hypertens Rep. 2010 Jun; 12(3):189-95.
    View in: PubMed
    Score: 0.018
  82. Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, Inusah S, Gupta H, Lloyd SG, Oparil S, Husain A, Dell'Italia LJ, Calhoun DA. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension. 2010 May; 55(5):1137-42.
    View in: PubMed
    Score: 0.018
  83. Calhoun DA, Crikelair NA, Yen J, Glazer RD. Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety. Adv Ther. 2009 Nov; 26(11):1012-23.
    View in: PubMed
    Score: 0.018
  84. Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010 Aug; 24(8):532-7.
    View in: PubMed
    Score: 0.018
  85. Czarina Acelajado M, Calhoun DA. Treatment of resistant hypertension. Minerva Cardioangiol. 2009 Dec; 57(6):787-812.
    View in: PubMed
    Score: 0.018
  86. Pisoni R, Ahmed MI, Calhoun DA. Characterization and treatment of resistant hypertension. Curr Cardiol Rep. 2009 Nov; 11(6):407-13.
    View in: PubMed
    Score: 0.017
  87. Ahmed MI, Pisoni R, Calhoun DA. Current options for the treatment of resistant hypertension. Expert Rev Cardiovasc Ther. 2009 Nov; 7(11):1385-93.
    View in: PubMed
    Score: 0.017
  88. Calhoun DA. Use of single-pill combination therapy in the evolving paradigm of hypertension management. Expert Opin Pharmacother. 2009 Aug; 10(12):1869-74.
    View in: PubMed
    Score: 0.017
  89. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009 Sep; 54(3):475-81.
    View in: PubMed
    Score: 0.017
  90. Acelajado MC, Calhoun DA. Resistant hypertension: who and how to evaluate. Curr Opin Cardiol. 2009 Jul; 24(4):340-4.
    View in: PubMed
    Score: 0.017
  91. Calhoun DA, Lacourci?re Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009 Jul; 54(1):32-9.
    View in: PubMed
    Score: 0.017
  92. Pimenta E, Calhoun DA. Aldosterone and metabolic dysfunction: an unresolved issue. Hypertension. 2009 Apr; 53(4):585-6.
    View in: PubMed
    Score: 0.017
  93. Gaddam KK, Pimenta E, Husain S, Calhoun DA. Aldosterone and cardiovascular disease. Curr Probl Cardiol. 2009 Feb; 34(2):51-84.
    View in: PubMed
    Score: 0.017
  94. Gonzaga CC, Calhoun DA. Resistant hypertension and hyperaldosteronism. Curr Hypertens Rep. 2008 Dec; 10(6):496-503.
    View in: PubMed
    Score: 0.016
  95. Gonzaga CC, Calhoun DA. 2008 American Heart Association Statement on diagnosis, evaluation, and treatment of resistant hypertension: what should we remember in everyday practice? Pol Arch Med Wewn. 2008 Jul-Aug; 118(7-8):396-7.
    View in: PubMed
    Score: 0.016
  96. Calhoun DA, Glazer RD, Pettyjohn FS, Coenen PD, Zhao Y, Grosso A. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Curr Med Res Opin. 2008 Aug; 24(8):2303-11.
    View in: PubMed
    Score: 0.016
  97. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008 Jun 24; 117(25):e510-26.
    View in: PubMed
    Score: 0.016
  98. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008 Jun 09; 168(11):1159-64.
    View in: PubMed
    Score: 0.016
  99. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008 Jun; 51(6):1403-19.
    View in: PubMed
    Score: 0.016
  100. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, Calhoun DA. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008 Feb; 51(2):339-44.
    View in: PubMed
    Score: 0.015
  101. Ahmed A, Calhoun D. High blood pressure in older adults: a conversation with Dr David Calhoun. Am J Geriatr Cardiol. 2007 Nov-Dec; 16(6):391-2.
    View in: PubMed
    Score: 0.015
  102. Pimenta E, Calhoun DA. Resistant hypertension and aldosteronism. Curr Hypertens Rep. 2007 Nov; 9(5):353-9.
    View in: PubMed
    Score: 0.015
  103. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Cofield SS, Oparil S, Calhoun DA. Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens. 2007 Oct; 25(10):2131-7.
    View in: PubMed
    Score: 0.015
  104. Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro. Hypertension. 2007 Sep; 50(3):447-53; discussion 447-53.
    View in: PubMed
    Score: 0.015
  105. Epstein M, Calhoun DA. The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy. Curr Hypertens Rep. 2007 Apr; 9(2):98-105.
    View in: PubMed
    Score: 0.015
  106. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007 Feb; 131(2):453-9.
    View in: PubMed
    Score: 0.014
  107. Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich). 2007 Jan; 9(1 Suppl 1):19-24.
    View in: PubMed
    Score: 0.014
  108. Calhoun DA. Aldosterone and cardiovascular disease: smoke and fire. Circulation. 2006 Dec 12; 114(24):2572-4.
    View in: PubMed
    Score: 0.014
  109. Pimenta E, Calhoun DA. Primary aldosteronism: diagnosis and treatment. J Clin Hypertens (Greenwich). 2006 Dec; 8(12):887-93.
    View in: PubMed
    Score: 0.014
  110. Calhoun DA. Aldosteronism and hypertension. Clin J Am Soc Nephrol. 2006 Sep; 1(5):1039-45.
    View in: PubMed
    Score: 0.014
  111. Pimenta E, Calhoun DA. Aldosterone, dietary salt, and renal disease. Hypertension. 2006 Aug; 48(2):209-10.
    View in: PubMed
    Score: 0.014
  112. Calhoun DA. Use of aldosterone antagonists in resistant hypertension. Prog Cardiovasc Dis. 2006 May-Jun; 48(6):387-96.
    View in: PubMed
    Score: 0.014
  113. Gaddam KK, Pratt-Ubunama MN, Calhoun DA. Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension. Expert Rev Cardiovasc Ther. 2006 May; 4(3):353-9.
    View in: PubMed
    Score: 0.014
  114. Nishizaka MK, Calhoun DA. Cardiovascular risk of systolic versus diastolic blood pressure in Western and non-Western countries. J Hypertens. 2006 Mar; 24(3):435-6.
    View in: PubMed
    Score: 0.014
  115. Calhoun DA. Resistant or difficult-to-treat hypertension. J Clin Hypertens (Greenwich). 2006 Mar; 8(3):181-6.
    View in: PubMed
    Score: 0.014
  116. Nishizaka MK, Calhoun DA. Primary aldosteronism: diagnostic and therapeutic considerations. Curr Cardiol Rep. 2005 Nov; 7(6):412-7.
    View in: PubMed
    Score: 0.013
  117. Nishizaka MK, Calhoun DA. The role of aldosterone antagonists in the management of resistant hypertension. Curr Hypertens Rep. 2005 Oct; 7(5):343-7.
    View in: PubMed
    Score: 0.013
  118. Pratt-Ubunama MN, Nishizaka MK, Calhoun DA. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering. Curr Hypertens Rep. 2005 Jun; 7(3):186-92.
    View in: PubMed
    Score: 0.013
  119. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005 Jun; 18(6):805-12.
    View in: PubMed
    Score: 0.013
  120. Calhoun DA, Grassi G. Weight gain and hypertension: the chicken-egg question revisited. J Hypertens. 2004 Oct; 22(10):1869-71.
    View in: PubMed
    Score: 0.012
  121. Nishizaka MK, Calhoun DA. Use of aldosterone antagonists in resistant hypertension. J Clin Hypertens (Greenwich). 2004 Aug; 6(8):458-60.
    View in: PubMed
    Score: 0.012
  122. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004 Jun 15; 109(23):2857-61.
    View in: PubMed
    Score: 0.012
  123. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004 Mar; 43(3):518-24.
    View in: PubMed
    Score: 0.012
  124. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest. 2004 Jan; 125(1):112-7.
    View in: PubMed
    Score: 0.012
  125. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003 Nov 04; 139(9):761-76.
    View in: PubMed
    Score: 0.012
  126. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003 Nov; 16(11 Pt 1):925-30.
    View in: PubMed
    Score: 0.012
  127. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002 Dec; 40(6):892-6.
    View in: PubMed
    Score: 0.011
  128. Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep. 2002 Jun; 4(3):221-8.
    View in: PubMed
    Score: 0.010
  129. Matanes F, Khan MB, Siddiqui M, Dudenbostel T, Calhoun D, Oparil S. An Update on Refractory Hypertension. Curr Hypertens Rep. 2022 07; 24(7):225-234.
    View in: PubMed
    Score: 0.010
  130. Gamble FN, Aufan MR, Sharifov OF, Williams LJ, Reighard S, Calhoun DA, Gupta H, Dell'Italia LJ, Denney TS, Lloyd SG. Diastolic function: modeling left ventricular untwisting as a damped harmonic oscillator. Physiol Meas. 2022 03 07; 43(2).
    View in: PubMed
    Score: 0.010
  131. Grassi G, Calhoun DA. Sympathetic-vascular interactions: further evidence in kidney transplantation. J Hypertens. 2002 Mar; 20(3):379-81.
    View in: PubMed
    Score: 0.010
  132. Kwon Y, Baruch M, Stafford PL, Bonner H, Cho Y, Mazimba S, Logan JG, Shimbo D, Park SH, Lin GM, Azarbarzin A, Calhoun DA, Berry R, Carey RM. Elucidation of obstructive sleep apnoea related blood pressure surge using a novel continuous beat-to-beat blood pressure monitoring system. J Hypertens. 2022 03 01; 40(3):520-527.
    View in: PubMed
    Score: 0.010
  133. Butts B, Brown JA, Denney TS, Ballinger S, Lloyd SG, Oparil S, Sanders P, Merriman TR, Gaffo A, Singh J, Kelley EE, Calhoun DA, Dell'Italia LJ. Racial Differences in XO (Xanthine Oxidase) and Mitochondrial DNA Damage-Associated Molecular Patterns in Resistant Hypertension. Hypertension. 2022 04; 79(4):775-784.
    View in: PubMed
    Score: 0.010
  134. Maheshwari A, Christensen RD, Calhoun DA. Immune-mediated neutropenia in the neonate. Acta Paediatr Suppl. 2002; 91(438):98-103.
    View in: PubMed
    Score: 0.010
  135. Aryal SR, Siddiqui M, Sharifov OF, Coffin MD, Zhang B, Gaddam KK, Gupta H, Denney TS, Dell'Italia LJ, Oparil S, Calhoun DA, Lloyd SG. Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change. J Am Heart Assoc. 2021 09 07; 10(17):e019434.
    View in: PubMed
    Score: 0.010
  136. Calhoun DA, Gersting JA, Lun?e M, Du Y, Christensen RD. Transfer of recombinant human granulocyte colony stimulating factor (rhG-CSF) from the maternal to the fetal circulation is not dependent upon a functional G-CSF-receptor. Placenta. 2001 Jul; 22(6):609-12.
    View in: PubMed
    Score: 0.010
  137. Gaffo AL, Calhoun DA, Rahn EJ, Oparil S, Li P, Dudenbostel T, Feig DI, Redden DT, Muntner P, Foster PJ, Biggers-Clark SR, Mudano A, Sattui SE, Saddekni MB, Bridges SL, Saag KG. Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial. Arthritis Rheumatol. 2021 08; 73(8):1514-1522.
    View in: PubMed
    Score: 0.010
  138. Santillan MK, Becker RC, Calhoun DA, Cowley AW, Flynn JT, Grobe JL, Kotchen TA, Lackland DT, Leslie KK, Liang M, Mattson DL, Meyers KE, Mitsnefes MM, Muntner PM, Pierce GL, Pollock JS, Sigmund CD, Thomas SJ, Urbina EM, Kidambi S. Team Science: American Heart Association's Hypertension Strategically Focused Research Network Experience. Hypertension. 2021 06; 77(6):1857-1866.
    View in: PubMed
    Score: 0.010
  139. Cai A, Liu L, Siddiqui M, Zhou D, Chen J, Calhoun DA, Tang S, Zhou Y, Feng Y. Uric Acid Is Not Associated With Blood Pressure Phenotypes and Target Organ Damage According to Blood Pressure Phenotypes. Am J Hypertens. 2021 02 18; 34(1):64-72.
    View in: PubMed
    Score: 0.010
  140. Calhoun DA, Chegini N, Polliotti BM, Gersting JA, Miller RK, Christensen RD. Granulocyte colony-stimulating factor in preterm and term pregnancy, parturition, and intra-amniotic infection. Obstet Gynecol. 2001 Feb; 97(2):229-34.
    View in: PubMed
    Score: 0.010
  141. Calhoun DA, Juul SE, McBryde EV, Veerman MW, Christensen RD. Stability of filgrastim and epoetin alfa in a system designed for enteral administration in neonates. Ann Pharmacother. 2000 Nov; 34(11):1257-61.
    View in: PubMed
    Score: 0.009
  142. Thomas SJ, Johnson DA, Guo N, Abdalla M, Booth JN, Spruill TM, Jackson CL, Yano Y, Sims M, Calhoun D, Muntner P, Redline S. Association of Obstructive Sleep Apnea With Nighttime Blood Pressure in African Americans: The Jackson Heart Study. Am J Hypertens. 2020 10 21; 33(10):949-957.
    View in: PubMed
    Score: 0.009
  143. Langford AT, Akinyelure OP, Moore TL, Howard G, Min YI, Hillegass WB, Bress AP, Tajeu GS, Butler M, Jaeger BC, Yano Y, Shimbo D, Ogedegbe G, Calhoun D, Booth JN, Muntner P. Underutilization of Treatment for Black Adults With Apparent Treatment-Resistant Hypertension: JHS and the REGARDS Study. Hypertension. 2020 11; 76(5):1600-1607.
    View in: PubMed
    Score: 0.009
  144. Calhoun DA, Christensen RD. Human developmental biology of granulocyte colony-stimulating factor. Clin Perinatol. 2000 Sep; 27(3):559-76, vi.
    View in: PubMed
    Score: 0.009
  145. Sullivan SE, Calhoun DA. Eosinophilia in the neonatal intensive care unit. Clin Perinatol. 2000 Sep; 27(3):603-22, vi.
    View in: PubMed
    Score: 0.009
  146. Calhoun DA, Christensen RD, Edstrom CS, Juul SE, Ohls RK, Schibler KR, Sola MC, Sullivan SE. Consistent approaches to procedures and practices in neonatal hematology. Clin Perinatol. 2000 Sep; 27(3):733-53.
    View in: PubMed
    Score: 0.009
  147. An J, Sim JJ, Calhoun DA, Liu R, Wei R, Zhou H, Luong T, Reynolds K. Apparent treatment-resistant hypertension: characteristics and prevalence in a real-world environment of an integrated health system. J Hypertens. 2020 08; 38(8):1603-1611.
    View in: PubMed
    Score: 0.009
  148. Siddiqui M, Dominiczak AF, Touyz RM, Carey RM, Basile J, Heslin MJ, Winokur T, Calhoun DA, Oparil S, Dudenbostel T. Case of Episodic and Positional Hypertension: Diagnosis and Treatment. Hypertension. 2020 09; 76(3):614-621.
    View in: PubMed
    Score: 0.009
  149. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med. 2020 07 07; 173(1):10-20.
    View in: PubMed
    Score: 0.009
  150. Calhoun DA, Sullivan SE, Lun?e M, Du Y, Christensen RD. Granulocyte-macrophage colony-stimulating factor and interleukin-5 concentrations in premature neonates with eosinophilia. J Perinatol. 2000 Apr-May; 20(3):166-71.
    View in: PubMed
    Score: 0.009
  151. Thomas SJ, Booth JN, Jaeger BC, Hubbard D, Sakhuja S, Abdalla M, Lloyd-Jones DM, Buysse DJ, Lewis CE, Shikany JM, Schwartz JE, Shimbo D, Calhoun D, Muntner P, Carnethon MR. Association of Sleep Characteristics With Nocturnal Hypertension and Nondipping Blood Pressure in the CARDIA Study. J Am Heart Assoc. 2020 04 07; 9(7):e015062.
    View in: PubMed
    Score: 0.009
  152. Calhoun DA, Lun?e M, Du Y, Hutson AD, Veerman M, Christensen RD. Granulocyte colony-stimulating factor serum and urine concentrations in neutropenic neonates before and after intravenous administration of recombinant granulocyte colony-stimulating factor. Pediatrics. 2000 Feb; 105(2):392-7.
    View in: PubMed
    Score: 0.009
  153. Calhoun DA, Lunoe M, Du Y, Christensen RD. Granulocyte colony-stimulating factor is present in human milk and its receptor is present in human fetal intestine. Pediatrics. 2000 Jan; 105(1):e7.
    View in: PubMed
    Score: 0.009
  154. Sharman JE, O'Brien E, Alpert B, Schutte AE, Delles C, Hecht Olsen M, Asmar R, Atkins N, Barbosa E, Calhoun D, Campbell NRC, Chalmers J, Benjamin I, Jennings G, Laurent S, Boutouyrie P, Lopez-Jaramillo P, McManus RJ, Mihailidou AS, Ordunez P, Padwal R, Palatini P, Parati G, Poulter N, Rakotz MK, Rosendorff C, Saladini F, Scuteri A, Sebba Barroso W, Cho MC, Sung KC, Townsend RR, Wang JG, Willum Hansen T, Wozniak G, Stergiou G. Lancet Commission on Hypertension group position statement on the global improvement of accuracy standards for devices that measure blood pressure. J Hypertens. 2020 01; 38(1):21-29.
    View in: PubMed
    Score: 0.009
  155. Calhoun DA, Lun?e M, Du Y, Staba SL, Christensen RD. Concentrations of granulocyte colony-stimulating factor in human milk after in vitro simulations of digestion. Pediatr Res. 1999 Dec; 46(6):767-71.
    View in: PubMed
    Score: 0.009
  156. Alper AB, Calhoun DA. Contemporary management of refractory hypertension. Curr Hypertens Rep. 1999 Oct; 1(5):402-7.
    View in: PubMed
    Score: 0.009
  157. Buhnerkempe MG, Botchway A, Prakash V, Al-Akchar M, Nolasco Morales CE, Calhoun DA, Flack JM. Prevalence of refractory hypertension in the United States from 1999 to 2014. J Hypertens. 2019 09; 37(9):1797-1804.
    View in: PubMed
    Score: 0.009
  158. Calhoun DA, Donnelly WH, Du Y, Dame JB, Li Y, Christensen RD. Distribution of granulocyte colony-stimulating factor (G-CSF) and G-CSF-receptor mRNA and protein in the human fetus. Pediatr Res. 1999 Sep; 46(3):333-8.
    View in: PubMed
    Score: 0.009
  159. Grassi G, Calhoun DA, Mancia G, Carey RM. Resistant Hypertension Management: Comparison of the 2017 American and 2018 European High Blood Pressure Guidelines. Curr Hypertens Rep. 2019 07 18; 21(9):67.
    View in: PubMed
    Score: 0.009
  160. Navarro-Soriano C, Mart?nez-Garc?a MA, Torres G, Barb? F, Caballero-Eraso C, Lloberes P, Cambriles TD, Somoza M, Masa JF, Gonz?lez M, Ma?as E, de la Pe?a M, Garc?a-R?o F, Montserrat JM, Muriel A, Oscullo G, Olmos LF, Garc?a-Ortega A, Calhoun D, Campos-Rodriguez F. Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a Pragmatic Longitudinal Study. Hypertens Res. 2019 11; 42(11):1708-1715.
    View in: PubMed
    Score: 0.009
  161. Navarro-Soriano C, Mart?nez-Garc?a MA, Torres G, Barb? F, Caballero-Eraso C, Lloberes P, Diaz Cambriles T, Somoza M, Masa JF, Gonz?lez M, Ma?as E, de la Pe?a M, Garc?a-R?o F, Montserrat JM, Muriel A, Oscullo G, Feced Olmos L, Garc?a-Ortega A, Calhoun D, Campos-Rodriguez F. Effect of continuous positive airway pressure in patients with true refractory hypertension and sleep apnea: a post-hoc intention-to-treat analysis of the HIPARCO randomized clinical trial. J Hypertens. 2019 06; 37(6):1269-1275.
    View in: PubMed
    Score: 0.008
  162. Johnson DA, Thomas SJ, Abdalla M, Guo N, Yano Y, Rueschman M, Tanner RM, Mittleman MA, Calhoun DA, Wilson JG, Muntner P, Redline S. Association Between Sleep Apnea and Blood Pressure Control Among Blacks. Circulation. 2019 03 05; 139(10):1275-1284.
    View in: PubMed
    Score: 0.008
  163. Booth JN, Allen NB, Calhoun D, Carson AP, Deng L, Goff DC, Redden DT, Reis JP, Shimbo D, Shikany JM, Sidney S, Spring B, Lewis CE, Muntner P. Racial Differences in Maintaining Optimal Health Behaviors Into Middle Age. Am J Prev Med. 2019 03; 56(3):368-375.
    View in: PubMed
    Score: 0.008
  164. Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019 02; 73(2):424-431.
    View in: PubMed
    Score: 0.008
  165. Butts B, Calhoun DA, Denney TS, Lloyd SG, Gupta H, Gaddam KK, Aban I, Oparil S, Sanders PW, Patel R, Collawn JF, Dell'Italia LJ. Plasma xanthine oxidase activity is related to increased sodium and left ventricular hypertrophy in resistant hypertension. Free Radic Biol Med. 2019 04; 134:343-349.
    View in: PubMed
    Score: 0.008
  166. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN, White WB. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 11; 72(5):e53-e90.
    View in: PubMed
    Score: 0.008
  167. Calhoun DA, Christensen RD. A randomized pilot trial of administration of granulocyte colony-stimulating factor to women before preterm delivery. Am J Obstet Gynecol. 1998 Sep; 179(3 Pt 1):766-71.
    View in: PubMed
    Score: 0.008
  168. Smith SM, Gurka MJ, Calhoun DA, Gong Y, Pepine CJ, Cooper-DeHoff RM. Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. Am J Med. 2018 12; 131(12):1463-1472.e7.
    View in: PubMed
    Score: 0.008
  169. Thomas SJ, Booth JN, Dai C, Li X, Allen N, Calhoun D, Carson AP, Gidding S, Lewis CE, Shikany JM, Shimbo D, Sidney S, Muntner P. Cumulative Incidence of Hypertension by 55?Years of Age in Blacks and Whites: The CARDIA Study. J Am Heart Assoc. 2018 07 11; 7(14).
    View in: PubMed
    Score: 0.008
  170. Parikh V, Thaler E, Kato M, Gillespie MB, Nguyen S, Withrow K, Calhoun D, Soose R, Stevens D, Stevens S, Larsen C, Reddy M, Lakkireddy D. Early feasibility of hypoglossal nerve upper airway stimulator in patients with cardiac implantable electronic devices and continuous positive airway pressure-intolerant severe obstructive sleep apnea. Heart Rhythm. 2018 08; 15(8):1165-1170.
    View in: PubMed
    Score: 0.008
  171. Oparil S, Calhoun DA. Managing the patient with hard-to-control hypertension. Am Fam Physician. 1998 Mar 01; 57(5):1007-14, 1019-20.
    View in: PubMed
    Score: 0.008
  172. Irvin MR, Booth JN, Sims M, Bress AP, Abdalla M, Shimbo D, Calhoun DA, Muntner P. The association of nocturnal hypertension and nondipping blood pressure with treatment-resistant hypertension: The Jackson Heart Study. J Clin Hypertens (Greenwich). 2018 03; 20(3):438-446.
    View in: PubMed
    Score: 0.008
  173. Flack JM, Calhoun D, Schiffrin EL. The New ACC/AHA Hypertension Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Am J Hypertens. 2018 01 12; 31(2):133-135.
    View in: PubMed
    Score: 0.008
  174. Calhoun DA, Christensen RD. Recent advances in the pathogenesis and treatment of nonimmune neutropenias in the neonate. Curr Opin Hematol. 1998 Jan; 5(1):37-41.
    View in: PubMed
    Score: 0.008
  175. Armario P, Calhoun DA, Oliveras A, Blanch P, Vinyoles E, Banegas JR, Gorostidi M, Segura J, Ruilope LM, Dudenbostel T, de la Sierra A. Prevalence and Clinical Characteristics of Refractory Hypertension. J Am Heart Assoc. 2017 Dec 07; 6(12).
    View in: PubMed
    Score: 0.008
  176. Eirin A, Saad A, Woollard JR, Juncos LA, Calhoun DA, Tang H, Lerman A, Textor SC, Lerman LO. Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated With Elevated Urinary Mitochondrial-DNA Copy Number. Am J Hypertens. 2017 Nov 01; 30(11):1112-1119.
    View in: PubMed
    Score: 0.008
  177. Calhoun DA, Mutinga ML. Race, family history of hypertension, and sympathetic response to cold pressor testing. Blood Press. 1997 Jul; 6(4):209-13.
    View in: PubMed
    Score: 0.007
  178. Calhoun DA, Oparil S. High blood pressure in women. Int J Fertil Womens Med. 1997 May-Jun; 42(3):198-205.
    View in: PubMed
    Score: 0.007
  179. Wolley MJ, Pimenta E, Calhoun D, Gordon RD, Cowley D, Stowasser M. Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea. J Hum Hypertens. 2017 09; 31(9):561-567.
    View in: PubMed
    Score: 0.007
  180. Ghazi L, Oparil S, Calhoun DA, Lin CP, Dudenbostel T. Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant. Hypertension. 2017 05; 69(5):827-835.
    View in: PubMed
    Score: 0.007
  181. Thomas SJ, Booth JN, Bromfield SG, Seals SR, Spruill TM, Ogedegbe G, Kidambi S, Shimbo D, Calhoun D, Muntner P. Clinic and ambulatory blood pressure in a population-based sample of African Americans: the Jackson Heart Study. J Am Soc Hypertens. 2017 Apr; 11(4):204-212.e5.
    View in: PubMed
    Score: 0.007
  182. Calhoun DA, Christensen RD. The occurrence of Kostmann syndrome in preterm neonates. Pediatrics. 1997 Feb; 99(2):259-61.
    View in: PubMed
    Score: 0.007
  183. Vemulapalli S, Deng L, Patel MR, Kilgore ML, Jones WS, Curtis LH, Irvin MR, Svetkey LP, Shimbo D, Calhoun DA, Muntner P. National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertension. Am Heart J. 2017 Apr; 186:29-39.
    View in: PubMed
    Score: 0.007
  184. Ghazi L, Dudenbostel T, Xing D, Ejem D, Turner-Henson A, Joiner CI, Affuso O, Azuero A, Oparil S, Calhoun DA, Rice M, Hage FG. Assessment of vascular function in low socioeconomic status preschool children: a pilot study. J Am Soc Hypertens. 2017 02; 11(2):101-109.
    View in: PubMed
    Score: 0.007
  185. Calhoun DA, Li Y, Christensen RD. Effect of recombinant granulocyte colony-stimulating factor on erythropoiesis in the human fetus and neonate. Pediatr Res. 1996 Dec; 40(6):872-5.
    View in: PubMed
    Score: 0.007
  186. Calhoun DA, Li Y, Braylan RC, Christensen RD. Assessment of the contribution of the spleen to granulocytopoiesis and erythropoiesis of the mid-gestation human fetus. Early Hum Dev. 1996 Nov 21; 46(3):217-27.
    View in: PubMed
    Score: 0.007
  187. Bangalore S, Davis BR, Cushman WC, Pressel SL, Muntner PM, Calhoun DA, Kostis JB, Whelton PK, Probstfield JL, Rahman M, Black HR. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. Am J Med. 2017 Apr; 130(4):439-448.e9.
    View in: PubMed
    Score: 0.007
  188. Bhatt H, Ghazi L, Calhoun D, Oparil S. BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out? Curr Cardiol Rep. 2016 10; 18(10):98.
    View in: PubMed
    Score: 0.007
  189. Calhoun DA, Kirk JF, Christensen RD. Incidence, significance, and kinetic mechanism responsible for leukemoid reactions in patients in the neonatal intensive care unit: a prospective evaluation. J Pediatr. 1996 Sep; 129(3):403-9.
    View in: PubMed
    Score: 0.007
  190. Saddekni MB, Saag KG, Dudenbostel T, Oparil S, Calhoun DA, Sattui SE, Feig DI, Muntner P, Redden DT, Foster PJ, Rahn EJ, Biggers SR, Li P, Gaffo AL. The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale. Contemp Clin Trials. 2016 09; 50:238-44.
    View in: PubMed
    Score: 0.007
  191. Bhandari SK, Shi J, Molnar MZ, Rasgon SA, Derose SF, Kovesdy CP, Calhoun DA, Kalantar-Zadeh K, Jacobsen SJ, Sim JJ. Comparisons of sleep apnoea rate and outcomes among patients with resistant and non-resistant hypertension. Respirology. 2016 11; 21(8):1486-1492.
    View in: PubMed
    Score: 0.007
  192. Schiffrin EL, Calhoun DA, Flack JM. Do We Need a New Definition of Hypertension After SPRINT? Am J Hypertens. 2016 10; 29(10):1127-9.
    View in: PubMed
    Score: 0.007
  193. Corr?a NB, de Faria AP, Ritter AM, Sabbatini AR, Almeida A, Brunelli V, Calhoun DA, Moreno H, Modolo R. A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension. J Am Soc Hypertens. 2016 06; 10(6):510-516.e1.
    View in: PubMed
    Score: 0.007
  194. Calhoun DA, Rosa C, Christensen RD. Transplacental passage of recombinant human granulocyte colony-stimulating factor in women with an imminent preterm delivery. Am J Obstet Gynecol. 1996 Apr; 174(4):1306-11.
    View in: PubMed
    Score: 0.007
  195. Muntner P, Becker RC, Calhoun D, Chen D, Cowley AW, Flynn JT, Grobe JL, Kidambi S, Kotchen TA, Lackland DT, Leslie KK, Li Y, Liang M, Lloyd A, Mattson DL, Mendizabal B, Mitsnefes M, Nair A, Pierce GL, Pollock JS, Safford MM, Santillan MK, Sigmund CD, Thomas SJ, Urbina EM. Introduction to the American Heart Association's Hypertension Strategically Focused Research Network. Hypertension. 2016 Apr; 67(4):674-80.
    View in: PubMed
    Score: 0.007
  196. Krzywanski DM, Moellering DR, Westbrook DG, Dunham-Snary KJ, Brown J, Bray AW, Feeley KP, Sammy MJ, Smith MR, Schurr TG, Vita JA, Ambalavanan N, Calhoun D, Dell'Italia L, Ballinger SW. Endothelial Cell Bioenergetics and Mitochondrial DNA Damage Differ in Humans Having African or West Eurasian Maternal Ancestry. Circ Cardiovasc Genet. 2016 Feb; 9(1):26-36.
    View in: PubMed
    Score: 0.007
  197. Schiffrin EL, Calhoun DA, Flack JM, Ito S, Webb RC. A Message From the New Editorial Team at the American Journal of Hypertension. Am J Hypertens. 2016 Jan; 29(1):1.
    View in: PubMed
    Score: 0.007
  198. Calhoun DA, Oparil S. Racial differences in the pathogenesis of hypertension. Am J Med Sci. 1995 Dec; 310 Suppl 1:S86-90.
    View in: PubMed
    Score: 0.007
  199. Schiffrin EL, Calhoun DA, Flack JM. SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price. Am J Hypertens. 2016 Jan; 29(1):2-4.
    View in: PubMed
    Score: 0.007
  200. Calhoun DA, Christensen RD. Commonly asked questions regarding infections in neonates. Pediatr Ann. 1995 Nov; 24(11):583-6, 589-91.
    View in: PubMed
    Score: 0.007
  201. Ellis AC, Patterson M, Dudenbostel T, Calhoun D, Gower B. Effects of 6-month supplementation with ?-hydroxy-?-methylbutyrate, glutamine and arginine on vascular endothelial function of older adults. Eur J Clin Nutr. 2016 Feb; 70(2):269-73.
    View in: PubMed
    Score: 0.007
  202. Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, Jacobsen SJ. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015 Sep; 88(3):622-32.
    View in: PubMed
    Score: 0.006
  203. Calhoun DA, Oparil S. Hypertensive crisis since FDR--a partial victory. N Engl J Med. 1995 Apr 13; 332(15):1029-30.
    View in: PubMed
    Score: 0.006
  204. Yano Y, Ning H, Muntner P, Reis JP, Calhoun DA, Viera AJ, Levine DA, Jacobs DR, Shimbo D, Liu K, Greenland P, Lloyd-Jones D. Nocturnal Blood Pressure in Young Adults and Cognitive Function in Midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Hypertens. 2015 Oct; 28(10):1240-7.
    View in: PubMed
    Score: 0.006
  205. Howard VJ, Tanner RM, Anderson A, Irvin MR, Calhoun DA, Lackland DT, Oparil S, Muntner P. Apparent Treatment-resistant Hypertension Among Individuals with History of Stroke or Transient Ischemic Attack. Am J Med. 2015 Jul; 128(7):707-14.e2.
    View in: PubMed
    Score: 0.006
  206. Ashraf AP, Alvarez JA, Dudenbostel T, Calhoun D, Griffin R, Wang X, Hanks LJ, Gower BA. Associations between vascular health indices and serum total, free and bioavailable 25-hydroxyvitamin D in adolescents. PLoS One. 2014; 9(12):e114689.
    View in: PubMed
    Score: 0.006
  207. Muntner P, Lewis CE, Diaz KM, Carson AP, Kim Y, Calhoun D, Yano Y, Viera AJ, Shimbo D. Racial differences in abnormal ambulatory blood pressure monitoring measures: Results from the Coronary Artery Risk Development in Young Adults (CARDIA) study. Am J Hypertens. 2015 May; 28(5):640-8.
    View in: PubMed
    Score: 0.006
  208. Calhoun DA, Mutinga ML, Wyss JM, Oparil S. Muscle sympathetic nervous system activity in black and Caucasian hypertensive subjects. J Hypertens. 1994 Nov; 12(11):1291-6.
    View in: PubMed
    Score: 0.006
  209. Schiros CG, Desai RV, Venkatesh BA, Gaddam KK, Agarwal S, Lloyd SG, Calhoun DA, Denney TS, Dell'italia LJ, Gupta H. Left ventricular torsion shear angle volume analysis in patients with hypertension: a global approach for LV diastolic function. J Cardiovasc Magn Reson. 2014 Sep 26; 16:70.
    View in: PubMed
    Score: 0.006
  210. Gupta A, Schiros CG, Gaddam KK, Aban I, Denney TS, Lloyd SG, Oparil S, Dell'Italia LJ, Calhoun DA, Gupta H. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy. J Hum Hypertens. 2015 Apr; 29(4):241-6.
    View in: PubMed
    Score: 0.006
  211. Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, Probstfield JL, Sastrasinh S. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. J Am Soc Hypertens. 2014 Nov; 8(11):808-19.
    View in: PubMed
    Score: 0.006
  212. Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014 Nov; 64(5):1012-21.
    View in: PubMed
    Score: 0.006
  213. Modolo R, de Faria AP, Paganelli MO, Sabbatini AR, Barbaro NR, Nascimento BB, Ramos CD, Fontana V, Calhoun DA, Moreno H. Predictors of silent myocardial ischemia in resistant hypertensive patients. Am J Hypertens. 2015 Feb; 28(2):200-7.
    View in: PubMed
    Score: 0.006
  214. White WB, Turner JR, Sica DA, Bisognano JD, Calhoun DA, Townsend RR, Aronow HD, Bhatt DL, Bakris GL. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014 Oct; 8(10):743-57.
    View in: PubMed
    Score: 0.006
  215. Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, Jiang HH, Threlkeld RJ, Robertson KE, Geiger MJ. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014 Oct; 64(4):731-7.
    View in: PubMed
    Score: 0.006
  216. Diaz KM, Booth JN, Calhoun DA, Irvin MR, Howard G, Safford MM, Muntner P, Shimbo D. Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke study. Hypertension. 2014 Sep; 64(3):465-71.
    View in: PubMed
    Score: 0.006
  217. de la Sierra A, Calhoun DA, Vinyoles E, Banegas JR, de la Cruz JJ, Gorostidi M, Segura J, Ruilope LM. Heart rate and heart rate variability in resistant versus controlled hypertension and in true versus white-coat resistance. J Hum Hypertens. 2014 Jul; 28(7):416-20.
    View in: PubMed
    Score: 0.006
  218. Tanner RM, Calhoun DA, Bell EK, Bowling CB, Guti?rrez OM, Irvin MR, Lackland DT, Oparil S, McClellan W, Warnock DG, Muntner P. Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study. Am J Kidney Dis. 2014 May; 63(5):781-8.
    View in: PubMed
    Score: 0.006
  219. Judd EK, Calhoun DA, Warnock DG. Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. Semin Nephrol. 2014; 34(5):532-9.
    View in: PubMed
    Score: 0.006
  220. Calhoun DA, Mutinga ML, Collins AS, Wyss JM, Oparil S. Normotensive blacks have heightened sympathetic response to cold pressor test. Hypertension. 1993 Dec; 22(6):801-5.
    View in: PubMed
    Score: 0.006
  221. Santos RC, de Faria AP, Barbaro NR, Modolo R, Ferreira-Melo SE, Matos-Souza JR, Coelho OR, Yugar-Toledo JC, Fontana V, Calhoun D, Moreno H. Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension. Eur J Clin Pharmacol. 2014 Feb; 70(2):147-54.
    View in: PubMed
    Score: 0.006
  222. Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA, Kalantar-Zadeh K, Jacobsen SJ. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013 Oct; 88(10):1099-107.
    View in: PubMed
    Score: 0.006
  223. Tanner RM, Calhoun DA, Bell EK, Bowling CB, Guti?rrez OM, Irvin MR, Lackland DT, Oparil S, Warnock D, Muntner P. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013 Sep; 8(9):1583-90.
    View in: PubMed
    Score: 0.006
  224. Eirin A, Zhu XY, Woollard JR, Herrmann SM, Gloviczki ML, Saad A, Juncos LA, Calhoun DA, Rule AD, Lerman A, Textor SC, Lerman LO. Increased circulating inflammatory endothelial cells in blacks with essential hypertension. Hypertension. 2013 Sep; 62(3):585-91.
    View in: PubMed
    Score: 0.006
  225. Guichard JL, Clark D, Calhoun DA, Ahmed MI. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag. 2013; 9:321-31.
    View in: PubMed
    Score: 0.006
  226. Shimbo D, Levitan EB, Booth JN, Calhoun DA, Judd SE, Lackland DT, Safford MM, Oparil S, Muntner P. The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study. J Hypertens. 2013 Feb; 31(2):370-6.
    View in: PubMed
    Score: 0.005
  227. Calhoun DA. Hypertension in blacks: socioeconomic stress and sympathetic nervous system activity. Am J Med Sci. 1992 Nov; 304(5):306-11.
    View in: PubMed
    Score: 0.005
  228. Gorelick PB, Nyenhuis D, Materson BJ, Calhoun DA, Elliott WJ, Phillips RA, Taler SJ, Townsend RR. Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. J Am Soc Hypertens. 2012 Sep-Oct; 6(5):309-15.
    View in: PubMed
    Score: 0.005
  229. Irvin MR, Shimbo D, Mann DM, Reynolds K, Krousel-Wood M, Limdi NA, Lackland DT, Calhoun DA, Oparil S, Muntner P. Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich). 2012 Oct; 14(10):694-700.
    View in: PubMed
    Score: 0.005
  230. Alessi A, Brand?o AA, Coca A, Cordeiro AC, Cordeiro A, Nogueira AR, Di?genes de Magalh?es F, Feitosa A, Amodeo C, Saad Rodrigues CI, Rodrigues C, Calhoun DA, Calhoun D, Barbosa Coelho E, Barbosa E, Pimenta E, Muxfeldt E, Consolin-Colombo FM, Consolin-Colombo F, Salles G, Rosito G, Moreno H, Martin JF, Yugar JC, Aparecido Bortolotto L, Bortolotto L, Naz?rio Scala LC, Scala LC, Gon?alves de Sousa M, Souza Md, Gomes MA, Malachias MB, Gus M, Passarelli O, Jardim PC, Toscano PR, S?nchez RA, Sanchez R, Dischinger Miranda R, Miranda RD, P?voa R, Barroso WK. First Brazilian position on resistant hypertension. Arq Bras Cardiol. 2012 Jul; 99(1):576-85.
    View in: PubMed
    Score: 0.005
  231. Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2012 May; 59(5):926-33.
    View in: PubMed
    Score: 0.005
  232. Ahmed MI, Desai RV, Gaddam KK, Venkatesh BA, Agarwal S, Inusah S, Lloyd SG, Denney TS, Calhoun D, Dell'italia LJ, Gupta H. Relation of torsion and myocardial strains to LV ejection fraction in hypertension. JACC Cardiovasc Imaging. 2012 Mar; 5(3):273-81.
    View in: PubMed
    Score: 0.005
  233. Clark D, Guichard JL, Calhoun DA, Ahmed MI. Recent advancements in the treatment of resistant hypertension. Postgrad Med. 2012 Jan; 124(1):67-73.
    View in: PubMed
    Score: 0.005
  234. Textor SC, Gloviczki ML, Flessner MF, Calhoun DA, Glockner J, Grande JP, McKusick MA, Cha SS, Lerman LO. Association of filtered sodium load with medullary volumes and medullary hypoxia in hypertensive African Americans as compared with whites. Am J Kidney Dis. 2012 Feb; 59(2):229-37.
    View in: PubMed
    Score: 0.005
  235. Acelajado MC, Pisoni R, Dudenbostel T, Oparil S, Calhoun DA, Glasser SP. Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. J Am Soc Hypertens. 2012 Jan-Feb; 6(1):66-72.
    View in: PubMed
    Score: 0.005
  236. Sim JJ, Yan EH, Liu IL, Rasgon SA, Kalantar-Zadeh K, Calhoun DA, Derose SF. Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. J Hypertens. 2011 Aug; 29(8):1553-9.
    View in: PubMed
    Score: 0.005
  237. Oparil S, Calhoun DA. The calcium antagonists in the 1990s. An overview. Am J Hypertens. 1991 Jul; 4(7 Pt 2):396S-405S.
    View in: PubMed
    Score: 0.005
  238. Quinaglia T, Martins LC, Figueiredo VN, Santos RC, Yugar-Toledo JC, Martin JF, Demacq C, Pimenta E, Calhoun DA, Moreno H. Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. J Hum Hypertens. 2011 Nov; 25(11):656-64.
    View in: PubMed
    Score: 0.005
  239. Yugar-Toledo JC, Martin JF, Krieger JE, Pereira AC, Demacq C, Coelho OR, Pimenta E, Calhoun DA, J?nior HM. Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes. DNA Cell Biol. 2011 Aug; 30(8):555-64.
    View in: PubMed
    Score: 0.005
  240. Levine DA, Calhoun DA, Prineas RJ, Cushman M, Howard VJ, Howard G. Moderate waist circumference and hypertension prevalence: the REGARDS Study. Am J Hypertens. 2011 Apr; 24(4):482-8.
    View in: PubMed
    Score: 0.005
  241. Levine DA, Lewis CE, Williams OD, Safford MM, Liu K, Calhoun DA, Kim Y, Jacobs DR, Kiefe CI. Geographic and demographic variability in 20-year hypertension incidence: the CARDIA study. Hypertension. 2011 Jan; 57(1):39-47.
    View in: PubMed
    Score: 0.005
  242. Calhoun DA, Oparil S. Treatment of hypertensive crisis. N Engl J Med. 1990 Oct 25; 323(17):1177-83.
    View in: PubMed
    Score: 0.005
  243. Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, Demacq C, Pimenta E, Calhoun DA, Moreno H. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens. 2011 Sep; 25(9):532-8.
    View in: PubMed
    Score: 0.005
  244. Zappe DH, Palmer BF, Calhoun DA, Purkayastha D, Samuel R, Jamerson KA. Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension. J Hum Hypertens. 2010 Jul; 24(7):483-91.
    View in: PubMed
    Score: 0.004
  245. Acelajado MC, Calhoun DA, Oparil S. Reduction of blood pressure in patients with treatment-resistant hypertension. Expert Opin Pharmacother. 2009 Dec; 10(18):2959-71.
    View in: PubMed
    Score: 0.004
  246. Feng W, Nagaraj H, Gupta H, Lloyd SG, Aban I, Perry GJ, Calhoun DA, Dell'Italia LJ, Denney TS. A dual propagation contours technique for semi-automated assessment of systolic and diastolic cardiac function by CMR. J Cardiovasc Magn Reson. 2009 Aug 13; 11:30.
    View in: PubMed
    Score: 0.004
  247. Pimenta E, Calhoun DA, Oparil S. Sleep apnea, aldosterone, and resistant hypertension. Prog Cardiovasc Dis. 2009 Mar-Apr; 51(5):371-80.
    View in: PubMed
    Score: 0.004
  248. Oparil S, Calhoun DA. Hypertension. Dis Mon. 1989 Mar; 35(3):133-232.
    View in: PubMed
    Score: 0.004
  249. Flack JM, Calhoun DA, Satlin L, Barbier M, Hilkert R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens. 2009 Jul; 23(7):479-89.
    View in: PubMed
    Score: 0.004
  250. Biederman RW, Doyle M, Young AA, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell'Italia LJ. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. Hypertension. 2008 Aug; 52(2):279-86.
    View in: PubMed
    Score: 0.004
  251. White WB, Calhoun DA, Samuel R, Taylor AA, Zappe DH, Purkayastha D. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. J Clin Hypertens (Greenwich). 2008 Jun; 10(6):450-8.
    View in: PubMed
    Score: 0.004
  252. Li S, Chen SC, Shlipak M, Bakris G, McCullough PA, Sowers J, Stevens L, Jurkovitz C, McFarlane S, Norris K, Vassalotti J, Klag MJ, Brown WW, Narva A, Calhoun D, Johnson B, Obialo C, Whaley-Connell A, Becker B, Collins AJ. Low birth weight is associated with chronic kidney disease only in men. Kidney Int. 2008 Mar; 73(5):637-42.
    View in: PubMed
    Score: 0.004
  253. Pimenta E, Calhoun DA, Oparil S. Mechanisms and treatment of resistant hypertension. Arq Bras Cardiol. 2007 Jun; 88(6):683-92.
    View in: PubMed
    Score: 0.004
  254. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007 Jan; 25(1):217-26.
    View in: PubMed
    Score: 0.004
  255. Raitt MH, Connor WE, Morris C, Kron J, Halperin B, Chugh SS, McClelland J, Cook J, MacMurdy K, Swenson R, Connor SL, Gerhard G, Kraemer DF, Oseran D, Marchant C, Calhoun D, Shnider R, McAnulty J. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005 Jun 15; 293(23):2884-91.
    View in: PubMed
    Score: 0.003
  256. Egan BM, Papademetriou V, Wofford M, Calhoun D, Fernandes J, Riehle JE, Nesbitt S, Michelson E, Julius S. Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. Am J Hypertens. 2005 Jan; 18(1):3-12.
    View in: PubMed
    Score: 0.003
  257. Hicken BL, Calhoun DA, Barton JC, Tucker DC. Attitudes about and psychosocial outcomes of HFE genotyping for hemochromatosis. Genet Test. 2004; 8(2):90-7.
    View in: PubMed
    Score: 0.003
  258. Aqel RA, Zoghbi GJ, Baldwin SA, Auda WS, Calhoun DA, Coffey CS, Perry GJ, Iskandrian AE. Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization. J Hypertens. 2003 Jun; 21(6):1157-62.
    View in: PubMed
    Score: 0.003
  259. DeJesus V, Rios I, Davis C, Chen Y, Calhoun D, Zakeri Z, Hubbard K. Induction of apoptosis in human replicative senescent fibroblasts. Exp Cell Res. 2002 Mar 10; 274(1):92-9.
    View in: PubMed
    Score: 0.003
  260. Carter AR, Zhou ZH, Calhoun DA, Bubien JK. Hyperactive ENaC identifies hypertensive individuals amenable to amiloride therapy. Am J Physiol Cell Physiol. 2001 Nov; 281(5):C1413-21.
    View in: PubMed
    Score: 0.003
  261. Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther. 2001 Aug; 23(8):1166-79.
    View in: PubMed
    Score: 0.002
  262. Payami H, Lee N, Zareparsi S, Gonzales McNeal M, Camicioli R, Bird TD, Sexton G, Gancher S, Kaye J, Calhoun D, Swanson PD, Nutt J. Parkinson's disease, CYP2D6 polymorphism, and age. Neurology. 2001 May 22; 56(10):1363-70.
    View in: PubMed
    Score: 0.002
  263. Christensen RD, Calhoun DA, Rimsza LM. A practical approach to evaluating and treating neutropenia in the neonatal intensive care unit. Clin Perinatol. 2000 Sep; 27(3):577-601.
    View in: PubMed
    Score: 0.002
  264. Edstrom CS, Calhoun DA, Christensen RD. Expression of tissue factor pathway inhibitor in human fetal and placental tissues. Early Hum Dev. 2000 Aug; 59(2):77-84.
    View in: PubMed
    Score: 0.002
  265. Tebes CC, Mehta P, Calhoun DA, Richards DS. Congenital ischemic forearm necrosis associated with a compound presentation. J Matern Fetal Med. 1999 Sep-Oct; 8(5):231-3.
    View in: PubMed
    Score: 0.002
  266. Sola MC, Calhoun DA, Hutson AD, Christensen RD. Plasma thrombopoietin concentrations in thrombocytopenic and non-thrombocytopenic patients in a neonatal intensive care unit. Br J Haematol. 1999 Jan; 104(1):90-2.
    View in: PubMed
    Score: 0.002
  267. Sola MC, Juul SE, Meng YG, Garg S, Sims P, Calhoun DA, Dame JB, Christensen D. Thrombopoietin (Tpo) in the fetus and neonate: Tpo concentrations in preterm and term neonates, and organ distribution of Tpo and its receptor (c-mpl) during human fetal development. Early Hum Dev. 1999 Jan; 53(3):239-50.
    View in: PubMed
    Score: 0.002
  268. Slayton WB, Li Y, Calhoun DA, Juul SE, Iturraspe J, Braylan RC, Christensen RD. The first-appearance of neutrophils in the human fetal bone marrow cavity. Early Hum Dev. 1998 Dec; 53(2):129-44.
    View in: PubMed
    Score: 0.002
  269. Juul SE, Calhoun DA, Christensen RD. "Idiopathic neutropenia" in very low birthweight infants. Acta Paediatr. 1998 Sep; 87(9):963-8.
    View in: PubMed
    Score: 0.002
  270. Slayton WB, Juul SE, Calhoun DA, Li Y, Braylan RC, Christensen RD. Hematopoiesis in the liver and marrow of human fetuses at 5 to 16 weeks postconception: quantitative assessment of macrophage and neutrophil populations. Pediatr Res. 1998 Jun; 43(6):774-82.
    View in: PubMed
    Score: 0.002
  271. Li Y, Calhoun DA, Polliotti BM, Sola MC, al-Mulla Z, Christensen RD. Production of granulocyte colony-stimulating factor by the human placenta at various stages of development. Placenta. 1996 Nov; 17(8):611-7.
    View in: PubMed
    Score: 0.002
  272. Li Y, Juul SE, Morris-Wiman JA, Calhoun DA, Christensen RD. Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses. Pediatr Res. 1996 Sep; 40(3):376-80.
    View in: PubMed
    Score: 0.002
  273. Grassi G, Seravalle G, Calhoun DA, Bolla GB, Giannattasio C, Marabini M, Del Bo A, Mancia G. Mechanisms responsible for sympathetic activation by cigarette smoking in humans. Circulation. 1994 Jul; 90(1):248-53.
    View in: PubMed
    Score: 0.002
  274. Grassi G, Seravalle G, Calhoun DA, Mancia G. Physical training and baroreceptor control of sympathetic nerve activity in humans. Hypertension. 1994 Mar; 23(3):294-301.
    View in: PubMed
    Score: 0.001
  275. Grassi G, Seravalle G, Calhoun DA, Matturri M, Mancia G, Zanchetti A. Monitoring of sympathetic activity in man: physiology and pharmacology. Eur Heart J. 1992 Jun; 13 Suppl A:22-5.
    View in: PubMed
    Score: 0.001
  276. Grassi G, Seravalle G, Calhoun D, Bolla GB, Mancia G. Physical exercise in essential hypertension. Chest. 1992 May; 101(5 Suppl):312S-314S.
    View in: PubMed
    Score: 0.001
  277. Grassi G, Seravalle G, Calhoun DA, Bolla G, Mancia G. Cigarette smoking and the adrenergic nervous system. Clin Exp Hypertens A. 1992; 14(1-2):251-60.
    View in: PubMed
    Score: 0.001
  278. Grassi G, Seravalle G, Calhoun DA, Bolla GB, Zanchetti A, Mancia G. Alterations in sympathetic nerve traffic during cigarette-smoking in man: a preliminary report. J Hypertens Suppl. 1991 Dec; 9(6):S52-3.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support